Cargando…

Serum sickness–like reaction associated with mirabegron

Detalles Bibliográficos
Autores principales:	Tan, Marcus G., Burns, Bruce F., Glassman, Steven J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558296/ https://www.ncbi.nlm.nih.gov/pubmed/31205999 http://dx.doi.org/10.1016/j.jdcr.2019.04.010

Ejemplares similares

Serum sickness-like reaction associated with cefazolin
por: Brucculeri, Michael, et al.
Publicado: (2006)

A Case of Serum Sickness-Like Reaction and Anaphylaxis - Induced Simultaneously by Rifampin
por: Kim, Dong-Hyun, et al.
Publicado: (2014)

Multiple drugs: Serum sickness-like reaction and rebound effect: case report
Publicado: (2022)

Serum sickness-like reaction following an administration of the first dose of inactivated COVID19 vaccine
por: Chaijaras, Sasipim, et al.
Publicado: (2021)

Respiratory dysfunction following initiation of mirabegron: A case report
por: Malsin, Elizabeth S., et al.
Publicado: (2019)

Fluoxetine: Serum sickness-like disorder: case report
Publicado: (2021)

Serum Sickness-Like Reactions After Pneumococcal Vaccination
por: Chung, Bing-Syuan, et al.
Publicado: (2021)

Bupropion-Induced Delayed Hypersensitivity Serum Sickness-Like Reaction
por: Cartwright, Alyssa M, et al.
Publicado: (2023)

Serum sickness-like reaction associated with meropenem in a 3-year old child
por: Leo, Sara H, et al.
Publicado: (2010)

Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature Review
por: Sandhu, Amarpreet, et al.
Publicado: (2012)

Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020)

Rituximab: Serum sickness: case report
Publicado: (2020)

Serum Sickness-Like Reaction: Drug-Induced Cutaneous Disease in a Child
por: Galvão dos Santos de Araujo, Ana Carolina, et al.
Publicado: (2021)

Case Report of Serum Sickness-like Reaction following the First Dose of the Chimpanzee Adenovirus-Vectored AstraZeneca COVID-19 Vaccine, ChAdOx1
por: Alzaidi, Areej Awad, et al.
Publicado: (2023)

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
por: Kim, Seo-Yeon, et al.
Publicado: (2023)

Serum Sickness following Tetanus Toxoid Injection
por: alhawal, Saja, et al.
Publicado: (2021)

Serum Sickness-Like Reaction Associated With Acute Hepatitis B in a Previously Vaccinated Adult Male
por: Gupta, Rahul, et al.
Publicado: (2021)

Inaccuracies in the recently published review on mirabegron
por: Siddiqui, Emad
Publicado: (2013)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022)

Distinct Conformations of Mirabegron Determined by MicroED
por: Lin, Jieye, et al.
Publicado: (2023)

Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women
por: Halverson, Thomas, et al.
Publicado: (2022)

Dapsone/rituximab: Serum sickness and lack of efficacy: case report
Publicado: (2022)

Mirabegron: The most promising adipose tissue beiging agent
por: Bel, Jocelyn S., et al.
Publicado: (2021)

The role of in vitro testing in pharmacovigilance for ß-lactam-induced serum sickness-like reaction: A pilot study
por: Elzagallaai, Abdelbaset A., et al.
Publicado: (2022)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

The combined effect of metformin and mirabegron on diet‐induced obesity
por: Zhao, Xin‐Yuan, et al.
Publicado: (2023)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

SERUM SICKNESS IN RABBITS : I. MANIFESTATIONS OF SERUM SICKNESS
por: Fleisher, Mover S., et al.
Publicado: (1931)

Munchausen syndrome: Playing sick or sick player
por: Prakash, Jyoti, et al.
Publicado: (2014)

Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
por: Saba, Julie, et al.
Publicado: (2017)

Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
por: Yamanishi, Tomonori, et al.
Publicado: (2020)

The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors
por: Dehvari, Nodi, et al.
Publicado: (2020)

SERUM SICKNESS IN RABBITS : II. PRECIPITINOGEN AND PRECIPITINS IN RELATION TO APPEARANCE OF THE REACTION
por: Jones, Lloyd, et al.
Publicado: (1932)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

Mirabegron displays anticancer effects by globally browning adipose tissues
por: Sun, Xiaoting, et al.
Publicado: (2023)

Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report
por: Khatib, Mohamad Y., et al.
Publicado: (2020)

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy
por: Matsuo, Tomohiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_abbctjgems0cavb8ah3dnajlo1